ACADIA Pharmaceuticals Inc (ACAD.OQ)
ACAD.OQ on NASDAQ Stock Exchange Global Select Market
43.63USD
1:30am IST
43.63USD
1:30am IST
Change (% chg)
$0.76 (+1.77%)
$0.76 (+1.77%)
Prev Close
$42.87
$42.87
Open
$43.00
$43.00
Day's High
$44.43
$44.43
Day's Low
$43.00
$43.00
Volume
691,679
691,679
Avg. Vol
617,213
617,213
52-wk High
$58.67
$58.67
52-wk Low
$23.77
$23.77
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.43 | December | 7 Aug 2020 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 7 | 6 | 6 | 6 |
| (2) OUTPERFORM | 7 | 7 | 7 | 8 |
| (3) HOLD | 2 | 3 | 3 | 3 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.69 | 1.81 | 1.81 | 1.82 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 15 | 117.02 | 122.22 | 110.96 | 109.20 |
| Quarter Ending Dec-20 | 15 | 126.86 | 147.70 | 117.20 | 108.80 |
| Year Ending Dec-20 | 15 | 437.26 | 460.46 | 421.80 | 454.14 |
| Year Ending Dec-21 | 15 | 751.88 | 1,041.93 | 606.15 | 756.18 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | 16 | -0.43 | -0.34 | -0.51 | -0.28 |
| Quarter Ending Dec-20 | 16 | -0.43 | -0.22 | -0.60 | -0.30 |
| Year Ending Dec-20 | 16 | -1.87 | -1.62 | -1.98 | -1.20 |
| Year Ending Dec-21 | 16 | -0.51 | 1.20 | -1.89 | 0.50 |
| LT Growth Rate (%) | 1 | 25.00 | 25.00 | 25.00 | 28.10 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-20 | 91.07 | 90.07 | 1.00 | 1.10 |
| Quarter Ending Dec-19 | 96.76 | 98.33 | 1.56 | 1.62 |
| Quarter Ending Sep-19 | 88.49 | 94.59 | 6.10 | 6.89 |
| Quarter Ending Jun-19 | 72.12 | 83.21 | 11.08 | 15.36 |
| Quarter Ending Mar-19 | 60.69 | 62.96 | 2.27 | 3.74 |
| Earnings (per share) | ||||
| Quarter Ending Mar-20 | -0.48 | -0.57 | 0.09 | -18.68 |
| Quarter Ending Dec-19 | -0.36 | -0.34 | 0.02 | -6.31 |
| Quarter Ending Sep-19 | -0.40 | -0.29 | 0.11 | -27.77 |
| Quarter Ending Jun-19 | -0.45 | -0.38 | 0.07 | -16.39 |
| Quarter Ending Mar-19 | -0.52 | -0.59 | 0.07 | -12.49 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 117.02 | 117.02 | 117.32 | 117.32 | 109.20 |
| Quarter Ending Dec-20 | 126.86 | 126.86 | 126.83 | 126.83 | 108.80 |
| Year Ending Dec-20 | 437.26 | 437.26 | 437.76 | 437.76 | 454.14 |
| Year Ending Dec-21 | 751.88 | 751.88 | 728.39 | 728.39 | 756.18 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | -0.43 | -0.43 | -0.43 | -0.43 | -0.28 |
| Quarter Ending Dec-20 | -0.43 | -0.43 | -0.46 | -0.46 | -0.30 |
| Year Ending Dec-20 | -1.87 | -1.87 | -1.89 | -1.90 | -1.20 |
| Year Ending Dec-21 | -0.51 | -0.51 | -0.59 | -0.59 | 0.50 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-20 | 0 | 0 | 1 | 2 |
| Quarter Ending Dec-20 | 0 | 0 | 1 | 2 |
| Year Ending Dec-20 | 0 | 0 | 1 | 2 |
| Year Ending Dec-21 | 0 | 0 | 4 | 4 |
| Earnings | ||||
| Quarter Ending Sep-20 | 0 | 0 | 4 | 2 |
| Quarter Ending Dec-20 | 0 | 0 | 6 | 0 |
| Year Ending Dec-20 | 0 | 0 | 4 | 2 |
| Year Ending Dec-21 | 0 | 0 | 4 | 6 |
Earnings vs. 
Estimates- U.S. FDA accepts Acadia's application for dementia drug
- U.S. FDA accepts Acadia's application for dementia drug
- BRIEF-Acadia Submits Supplemental NDA To U.S. FDA For Nuplazid For Treatment Of Delusions Associated With Dementia-Related Psychosis
- BRIEF-Acadia Pharmaceuticals To Combine Clarity-2 And Clarity-3 Phase 3 Studies Evaluating Pimavanserin
- BRIEF-Acadia Pharmaceuticals Reports First Quarter 2020 Financial Results